183 related articles for article (PubMed ID: 20625817)
1. Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers.
Gutiérrez-Enríquez S; Ramón Y Cajal T; Alonso C; Corral A; Carrasco P; Cornet M; Sanz J; Ribas M; Baiget M; Diez O
Breast Cancer Res Treat; 2011 Jun; 127(3):611-22. PubMed ID: 20625817
[TBL] [Abstract][Full Text] [Related]
2. Chromosomal mutagen sensitivity associated with mutations in BRCA genes.
Speit G; Trenz K
Cytogenet Genome Res; 2004; 104(1-4):325-32. PubMed ID: 15162060
[TBL] [Abstract][Full Text] [Related]
3. Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families.
Rothfuss A; Schütz P; Bochum S; Volm T; Eberhardt E; Kreienberg R; Vogel W; Speit G
Cancer Res; 2000 Jan; 60(2):390-4. PubMed ID: 10667592
[TBL] [Abstract][Full Text] [Related]
4. Increased chromosomal radiosensitivity in women carrying BRCA1/BRCA2 mutations assessed with the G2 assay.
Ernestos B; Nikolaos P; Koulis G; Eleni R; Konstantinos B; Alexandra G; Michael K
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1199-205. PubMed ID: 20206018
[TBL] [Abstract][Full Text] [Related]
5. Lymphocytes of BRCA1 and BRCA2 germ-line mutation carriers, with or without breast cancer, are not abnormally sensitive to the chromosome damaging effect of moderate folate deficiency.
Beetstra S; Salisbury C; Turner J; Altree M; McKinnon R; Suthers G; Fenech M
Carcinogenesis; 2006 Mar; 27(3):517-24. PubMed ID: 16162645
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage.
Nieuwenhuis B; Van Assen-Bolt AJ; Van Waarde-Verhagen MA; Sijmons RH; Van der Hout AH; Bauch T; Streffer C; Kampinga HH
Int J Radiat Biol; 2002 Apr; 78(4):285-95. PubMed ID: 12020440
[TBL] [Abstract][Full Text] [Related]
7. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
[TBL] [Abstract][Full Text] [Related]
8. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
9. Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variability.
Lovelock PK; Wong EM; Sprung CN; Marsh A; Hobson K; French JD; Southey M; Sculley T; Pandeya N; Brown MA; Chenevix-Trench G; Spurdle AB; McKay MJ;
Breast Cancer Res Treat; 2007 Sep; 104(3):257-66. PubMed ID: 17063265
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
11. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
Salmon AY; Salmon-Divon M; Zahavi T; Barash Y; Levy-Drummer RS; Jacob-Hirsch J; Peretz T
Cancer Prev Res (Phila); 2013 Feb; 6(2):82-90. PubMed ID: 23341570
[TBL] [Abstract][Full Text] [Related]
12. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
13. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
14. CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.
Palanca Suela S; Esteban Cardeñosa E; Barragán González E; de Juan Jiménez I; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Montalar Salcedo J; Castel Sánchez V; Bolufer Gilabert P;
Breast Cancer Res Treat; 2010 Jan; 119(1):87-93. PubMed ID: 19214744
[TBL] [Abstract][Full Text] [Related]
15. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.
Barwell J; Pangon L; Georgiou A; Kesterton I; Langman C; Arden-Jones A; Bancroft E; Salmon A; Locke I; Kote-Jarai Z; Morris JR; Solomon E; Berg J; Docherty Z; Camplejohn R; Eeles R; Hodgson SV
Int J Cancer; 2007 Oct; 121(7):1631-6. PubMed ID: 17582599
[TBL] [Abstract][Full Text] [Related]
17. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
Antoniou AC; Shenton A; Maher ER; Watson E; Woodward E; Lalloo F; Easton DF; Evans DG
Breast Cancer Res; 2006; 8(6):R72. PubMed ID: 17187672
[TBL] [Abstract][Full Text] [Related]
18. A 24-color metaphase-based radiation assay discriminates heterozygous BRCA2 mutation carriers from controls by chromosomal radiosensitivity.
Becker AA; Graeser MK; Landwehr C; Hilger T; Baus W; Wappenschmidt B; Meindl A; Weber RG; Schmutzler RK
Breast Cancer Res Treat; 2012 Aug; 135(1):167-75. PubMed ID: 22729890
[TBL] [Abstract][Full Text] [Related]
19. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Kirova YM; Savignoni A; Sigal-Zafrani B; de La Rochefordiere A; Salmon RJ; This P; Asselain B; Stoppa-Lyonnet D; Fourquet A
Breast Cancer Res Treat; 2010 Feb; 120(1):119-26. PubMed ID: 20033769
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]